Carrie Kitko, MD, is the medical director for the Pediatric Stem Cell Transplantation Program at Vanderbilt University Medical Center.
Analysis Supports Flexible Axatilimab Use in Chronic GVHD, Calls for Combination Therapy Research: Carrie Kitko, MD
Carrie Kitko, MD, explains that axatilimab maintains strong response rates in patients with chronic graft-versus-host disease (GVHD) regardless of previous treatment lines and emphasizes the need to explore combination therapies.
Post Hoc Analysis Supports Axatilimab in Heavily Pretreated Patients With Chronic GVHD: Carrie Kitko, MD
The post hoc analysis of the AGAVE-201 trial found that axatilimab demonstrated consistent response rates in patients with chronic graft-vs-host disease (GVHD), regardless of the number or type of prior therapies.